|
|
|
|
Estrostep: More than a Pill!
Estrostep is an oral contraceptive or a birth control pill that prevent women of getting pregnant. It provides estrogens in a regulated sequence over 21 days by supplying a steady dose of progesterone. If taken properly, they have a failure rate of 1 %, which really demonstrates its effectiveness since the statistics, including women missing pills, have proven that the typical failure rate of users of other pills is of less than three percent. The tablet schedule provided by Estrostep is designed for women to have 1 week off after having 3 weeks on. In order to maximize the effectiveness of the pill, women should take the pill without interruption.
One of the main advantages of this pill is that Estrostep users rarely experiment side effects. Another advantageous feature that makes Estrostep one of the best oral contraceptives is that women can take it not only to prevent pregnancy, but also to moderate acne. With this purpose, it is important to know that women must be at least 15 years old, able to use pills, plan to use it for six months as a minimum, have started the period, have used other acne treatments without any result and desire to use the pill for birth control too. Moreover, several other non-contraceptive advantages are offered by Estrostep such as less anemia and menstrual blood loss, fewer cancers of the lining of the uterus and the ovary, less painful menstruation and fewer pelvic infections.
Women with particular situations who are taking Estrostep should look for medical assistance due to the fact that combining the pill with these circumstances may increase the possibilities of suffering permanent or temporary disability for developing some diseases. Those women who smoke, and have high cholesterol, blood pressure, liver tumors or cancer are included in this group.
View more Free Content by rxboomer at GetYourContent.com
Visit RxBoomer.com for information about various Prescription Drugs and/or Drug Companies.
Tags: Prescription Drugs : Health / Fitness
|
|
|
|
|
|
|